London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
You will only have one login account. Registering with multiple accounts is not allowed. Any user found to have more than one account on this site will have all, and any future accounts suspended permanently.
Your email and password must only be used by you. If a post is made under your account, it will be considered that it was posted by yourself.
Your account nickname must not be the same, or contain, listed company names or board members' names.
While debating and discussion is fine, we will not tolerate; rudeness, swearing, insulting posts, personal attacks, or posts which are invasive of another's privacy.
You will not;
discuss illegal or criminal activities.
post any confidential or price sensitive information or that is not public knowledge.
post misleading or false statements regarding the share price and performance. Such posts are deemed as market abuse, and may be reported to the appropriate authorities.
post any private communication, or part thereof, from any other person, including from a member of the board of directors of a listed company. Such posts cannot be verified as true and could be deemed to be misleading.
post any personal details (e.g. email address or phone number).
post live price or level 2 updates.
publish content that is not your original work, or infringes the copyright or other rights of any third party.
post non-constructive, meaningless, one word (or short) non-sense posts.
post links to, or otherwise publish any content containing any form of advertising, promotion for goods and services, spam, or other unsolicited communication.
post any affiliate or referral links, or post anything asking for a referral.
post or otherwise publish any content unrelated to the board or the board's topic.
re-post premium share chat posts on regular share chat.
restrict or inhibit any other user from using the boards.
impersonate any person or entity, including any of our employees or representatives.
post or transmit any content that contains software viruses, files or code designed to interrupt, destroy or limit the functionality of this website or any computer software or equipment.
If you are going to post non-English, please also post an English translation of your post.
If you are going to post non-English, please also post an English translation of your post.
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium and Verified Members
Premium Members are members that have a premium subscription with London South East and have access to Premium Chat. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I've just bought a small holding in Equals Group at 29.5p. Looks really cheap on forecast p/e of about 5. It's a recovery play on the travel sector if you think travel will open up next year. Other recovery shares have gone up a lot but this one has not yet.
Let me know what you think. There have been recent director buys as well.
Thanks for sharing Livecyte. I watched a webinar on it and it seems interesting. If i am right, it is a platform that aids the study of live cell behaviour. There were people from Hull University saying that they are very impressed with it in vivo (living organisms) and in vitro (test tube & lab dish). The equipment allows the users to study and observe cell behaviour in scratch wounds (in vitro) and live mouse models (in vivo). The latter where ovaries were removed from mice thus mimicking the menopause which didn't help poor mousey close the wound and recover to quickly. Then they did the same with another mouse in which oestrogen was introduced and it recovered more quickly. You could visibly see the cell behaviour in both which I thought was useful.
I think scientist would find it interesting if they thought it could simplify their studies and help them demonstrate the science more clearly. Not sure how investable it is as the idea seems to be aimed at scientists.
RMS - punt with huge upside Synairgen - My LTH and WILL multibag x10 at least by next June. Science rock solid and not just COVID stock IMM - FDA should approve P3 soon RDSA - Large safe rise in next 12 months, massive correction due IQAI - FDA approved product done and dusted. Mayo Clinic involved, strong connections in USA, good LT upside.
Hi Bojo Thanks for your reply, it looks very interesting. BRH have some interesting investments. Have you come across livecyte? Seems to be an amazing product. Could you cast your eye over this short video and let me know if you think it has commercial legs https://www.youtube.com/watch?v=lposS9SNngY
Parsortix is already playing a tiny part in fighting cancer which is the second biggest killer next to cardio vascular disease.
I have not heard that Parsortix is being used for anything else apart from cancer diagnosis and monitoring, but my suspicion is that Angle main targets will remain breast, colon, prostate and skin cancers due to restricted budgets. As a small company they are able to make very achievable progress in these areas that will be jet propelled by an FDA endorsement. Maybe then they can look at a proactive study but that would cost billions and take 10 to 15 years! When I say small, they are pretty well set up and connected world wide.
My own opinion on Covid 19 is that the big pharmas are taking care of that space. Pfizer Biontech, Moderna look to have vaccines that prevent the onset of the disease. There are several good treatments due for approval in the next 6 to 12 months. It looks like Novavax may have a vaccine that stops the spread! If that is true, then maybe Covids days may be numbered. Lets hope :-)
It is also worth bearing in mind that the Covid diagnostic space is very crowded. On the other hand, nobody else is able to capture live cancer cells apart from Angle. They remain the only company that are proven to do so.
Angle know there place. They are a tiny cog in a wheel that will help big pharma save lives, but oh what an important cog they may be!
I have one suggestion which is Angle PLC. Inflection point due some time after April 2021. Price 43p (-10p of late due to Jupiter selling) Product: Parsortix. Binary play
A totally UNIQUE developer of proactive liquid biopsy diagnostics tests AND machinery for LIVE cancer cells with over 35 PEER REVIEWS and 100,000.00 tests to date around the world as part of their DE NOVO submission to the FDA (hence beyond April 2021). Just think about it, less; stress, worry, time, medical procedures and money and resources it may save. Revenue already coming in...
Hi Bojo Hope you had a good week. I will give it a go. Having said this I am not watching that may shares so this may be my complete list:- 1 RMS (which other share would it be for me lol) If everything goes to plan short term multi bag. Rns x2 expected on new holder and orders/deals. next 2 weeks is critical for me. If we have a decent spike i think I may reduce, I am too old to hold this roller coaster share.
2 IMM Short term possible bag long term multi bag, all this is critical on FDA approval and successful phase 3
3 IQAI Short term possible bag Artificial imaging is they way forward and this company appears to be cutting adge. Big rns coming up maybe before the end of 2020 about cad free. If validated I can see this going to 50p plus
4 FDBK this is similar to IQAI but for portable devices main product is called Bleepa. if this starts to become standard in the NHS this will multi bag
DNL Slow burner at the moment FDA approval for Alkindi® Sprinkle. Not sure if the market has priced in the potential earnings. Recent placing so the have cash in the bank. This may start to come to life end of Dec, during January.
If you wish you can list your top five tips and why.
If we can limit the reasons why to two sentences that would be great. Also don't ramp it again unless some asks you for more information! Nothing worse than hearing about the same stock over and over again!
You can choose any sector and even 5 from one sector if you have too.